Boeri E - Search Results

1

Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.

Canducci F, Barda B, Ceresola E, Spagnuolo V, Sampaolo M, Boeri E, Nozza S, Cossarin F, Galli A, Gianotti N, Castagna A, Lazzarin A, Clementi M. Canducci F, et al. Among authors: boeri e. Clin Microbiol Infect. 2011 Jun;17(6):928-34. doi: 10.1111/j.1469-0691.2010.03375.x. Epub 2010 Nov 5. Clin Microbiol Infect. 2011. PMID: 20854427 Free article.

2

Redistribution of human immunodeficiency virus type 1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen.

Gianotti N, Seminari E, Lazzarin A, Boeri E, Clementi M, Danise A, Salpietro S, Fusetti G, Castagna A. Gianotti N, et al. Among authors: boeri e. AIDS Res Hum Retroviruses. 2005 Jun;21(6):545-54. doi: 10.1089/aid.2005.21.545. AIDS Res Hum Retroviruses. 2005. PMID: 15989459 Clinical Trial.

3

Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.

Canducci F, Sampaolo M, Marinozzi MC, Boeri E, Spagnuolo V, Galli A, Castagna A, Lazzarin A, Clementi M, Gianotti N. Canducci F, et al. Among authors: boeri e. AIDS. 2009 Feb 20;23(4):455-60. doi: 10.1097/QAD.0b013e328323da60. AIDS. 2009. PMID: 19165083

4

Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.

Canducci F, Marinozzi MC, Sampaolo M, Boeri E, Spagnuolo V, Gianotti N, Castagna A, Paolucci S, Baldanti F, Lazzarin A, Clementi M. Canducci F, et al. Among authors: boeri e. J Antimicrob Chemother. 2010 Mar;65(3):425-33. doi: 10.1093/jac/dkp477. Epub 2010 Jan 7. J Antimicrob Chemother. 2010. PMID: 20056687

5

Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.

Canducci F, Ceresola ER, Boeri E, Spagnuolo V, Cossarini F, Castagna A, Lazzarin A, Clementi M. Canducci F, et al. Among authors: boeri e. J Infect Dis. 2011 Dec 1;204(11):1811-5. doi: 10.1093/infdis/jir636. Epub 2011 Oct 7. J Infect Dis. 2011. PMID: 21984737

6

Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure.

Boeri E, Gianotti N, Canducci F, Hasson H, Giudici B, Castagna A, Lazzarin A, Clementi M. Boeri E, et al. AIDS Res Hum Retroviruses. 2003 Dec;19(12):1151-3. doi: 10.1089/088922203771881257. AIDS Res Hum Retroviruses. 2003. PMID: 14714567

7

Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients.

Hasson H, Gianotti N, Danise A, Seminari E, Boeri E, Nozza S, Castagna A, Lazzarin A. Hasson H, et al. Among authors: boeri e. AIDS. 2004 Jan 2;18(1):123-7. doi: 10.1097/00002030-200401020-00016. AIDS. 2004. PMID: 15090838

8

The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.

Castagna A, Gianotti N, Galli L, Danise A, Hasson H, Boeri E, Hoetelmans R, Nauwelaers D, Lazzarin A. Castagna A, et al. Among authors: boeri e. Antivir Ther. 2004 Aug;9(4):537-43. Antivir Ther. 2004. PMID: 15456085 Clinical Trial.

9

Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients.

Gianotti N, Seminari E, Fusetti G, Salpietro S, Boeri E, Galli A, Lazzarin A, Clementi M, Castagna A. Gianotti N, et al. Among authors: boeri e. AIDS. 2004 Nov 5;18(16):2205-8. doi: 10.1097/00002030-200411050-00016. AIDS. 2004. PMID: 15577657

10

Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.

Gianotti N, Seminari E, Guffanti M, Boeri E, Villani P, Regazzi M, Bigoloni A, Schira G, Tiberi S, Fusetti G, Lazzarin A, Castagna A. Gianotti N, et al. Among authors: boeri e. New Microbiol. 2005 Apr;28(2):119-25. New Microbiol. 2005. PMID: 16035256 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

170 results

Search Page